Implantable Cardioverter-Defibrillators (ICDs)

Implantable cardioverter-defibrillators are small, battery-powered devices surgically placed beneath the skin to monitor heart rhythm and deliver electrical therapy when life-threatening arrhythmias are detected. This page covers how ICDs are classified, how they detect and terminate dangerous rhythms, the clinical scenarios that prompt implantation, and the criteria that guide patient selection. Understanding ICD function is essential for anyone navigating a diagnosis of cardiomyopathy, ventricular arrhythmia, or sudden cardiac arrest survival, and it sits at the intersection of device engineering, electrophysiology, and federal regulatory oversight.

Definition and scope

An ICD is a permanently implanted cardiac rhythm management device capable of delivering three distinct forms of electrical therapy: low-energy antitachycardia pacing (ATP), synchronized cardioversion, and high-energy defibrillation. The device continuously monitors cardiac electrical activity through one or more leads positioned in or on the heart and applies therapy automatically when a programmed rhythm criterion is met.

The U.S. Food and Drug Administration (FDA) classifies ICDs as Class III medical devices under 21 CFR Part 870, the highest risk classification requiring premarket approval (PMA) before commercial distribution. This classification reflects the device's direct life-sustaining function and the severity of consequences associated with malfunction. The broader regulatory context for cardiology — including FDA oversight of cardiac devices and Centers for Medicare & Medicaid Services (CMS) coverage criteria — directly shapes which patients qualify for implantation under insured care pathways.

Three principal device architectures exist within the ICD category:

  1. Transvenous ICD (TV-ICD): Leads are inserted through a vein and positioned in the right ventricle, right atrium, or coronary sinus. The generator is implanted subcutaneously, typically in the left pectoral region. This is the most established configuration.
  2. Subcutaneous ICD (S-ICD): No leads enter the vasculature or heart chambers; sensing and shock electrodes run subcutaneously along the left sternal border. The Boston Scientific EMBLEM S-ICD received FDA approval in 2012 and is appropriate when pacing is not required.
  3. Extravascular ICD (EV-ICD): A lead is tunneled substernally without entering the venous system, combining defibrillation capability with antitachycardia pacing. The Medtronic EV-ICD received FDA approval in 2023.

Cardiac resynchronization therapy defibrillators (CRT-D) add a third lead in the left ventricular branch of the coronary sinus and are used when concomitant heart failure with reduced ejection fraction and ventricular dyssynchrony are present.

How it works

An ICD continuously analyzes intracardiac electrograms (or subcutaneous electrograms in the S-ICD) and compares detected cycle lengths against programmed detection zones. The Heart Rhythm Society (HRS) and device programming guidelines define standard detection zones as the ventricular fibrillation (VF) zone — typically cycle lengths below 320 milliseconds, corresponding to rates above 188 beats per minute — and one or more ventricular tachycardia (VT) zones at slower rates.

When a detected rhythm falls within a programmed zone, the ICD executes a therapy hierarchy:

  1. Antitachycardia pacing (ATP): Rapid pacing bursts at a rate slightly faster than the tachycardia attempt to interrupt a reentrant VT circuit without shock delivery. ATP terminates hemodynamically stable VT in approximately 90% of episodes per data reported in the landmark EMPIRIC trial (published in Heart Rhythm, 2006).
  2. Cardioversion: A synchronized low-energy shock (typically 0.5–5 joules) is delivered timed to the R-wave for organized rhythms that do not respond to ATP.
  3. Defibrillation: An unsynchronized high-energy shock (up to 35–40 joules in most contemporary devices) is used for VF or VT that does not have a detectable R-wave.

All therapies are logged in device memory with stored electrograms, enabling clinicians to review appropriateness at follow-up via remote monitoring platforms or in-person interrogation using a device programmer. Remote monitoring is addressed in HRS expert consensus documents (HRS Remote Monitoring Statement, 2015).

Common scenarios

ICD implantation occurs in two broad clinical frameworks: secondary prevention and primary prevention.

Secondary prevention applies to patients who have already experienced sustained VT with hemodynamic compromise, VF, or survived sudden cardiac arrest (SCA) not attributable to a reversible cause. The AVID trial (NEJM, 1997) demonstrated a mortality reduction favoring ICD over antiarrhythmic drug therapy in this population.

Primary prevention applies to patients at elevated risk of sudden cardiac death who have not yet experienced a qualifying event. The most common indication is reduced left ventricular ejection fraction (LVEF) — specifically LVEF ≤ 35% — in the setting of ischemic or non-ischemic cardiomyopathy with NYHA functional class II or III heart failure despite at least 3 months of guideline-directed medical therapy. The MADIT-II trial (NEJM, 2002) established primary prevention benefit in ischemic cardiomyopathy with LVEF ≤ 30%.

Additional indications include inherited arrhythmia syndromes — such as hypertrophic cardiomyopathy, Brugada syndrome, long QT syndrome, and arrhythmogenic right ventricular cardiomyopathy — where sudden death risk stratification is performed according to condition-specific criteria published by HRS and the European Heart Rhythm Association (EHRA).

Decision boundaries

Not all patients with reduced LVEF or arrhythmia history are candidates for ICD implantation. The decision framework involves multiple intersecting criteria:

The comprehensive overview of cardiology specialties and resources available at cardiologyauthority.com contextualizes ICD therapy within the full landscape of electrophysiology, atrial fibrillation and arrhythmia management, and living with a pacemaker or ICD after implantation. Comparison with pacemakers is frequently necessary, as the two device classes share lead systems but differ fundamentally in therapeutic purpose: pacemakers address bradycardia by delivering low-energy pacing stimuli, while ICDs address tachyarrhythmias through high-energy shock delivery and ATP, with optional backup pacing as a secondary function.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)